MARIJUANA IMPAIRMENT SCREENING TECHNOLOGY SOON TO BE EXPANDED TO INCLUDE OPIOIDS

Scottsdale, Arizona - July 15, 2019 - ZXEREX® CORPORATION announces the development of a unique bio-signature that reveals temporary neurological impairment, strongly associated with the use of marijuana. Using a combination of traditional biostatistical analysis, deep machine learning, and artificial intelligence, ZXEREX will soon release IMPAIR-ID™, a screening technology that can identify marijuana intoxication.

This disruptive development provides a rapid, non-invasive, and inexpensive way to screening for workers with jobs in which marijuana use poses significant risk to themselves, co-workers, and the public.

When combined with a workplace safety program, this screening capability has the potential to reduce workplace accidents and injuries in manufacturing, construction, energy, transportation, and healthcare.

The company’s initial human subject research was performed at the SUNY Downstate Medical Center and Columbia University.

ZXEREX plans to conduct additional studies to identify bio-signatures for opioids in opioid-naïve and opioid-tolerant human subjects. In addition, the company will study the combined effects of alcohol and marijuana which are known to substantially increase risk. Prior research and analysis of highway fatalities in a recent GHSA study, funded by the Foundation for Advancing Alcohol Responsibility, showed in 2016, that 48.5% of fatalities that involved alcohol, also included other drugs such as marijuana, opioids or both.

The ability to identify impairment when combined with an employer’s safety program can help to reduce workplace injuries, lower absenteeism, lower casualty loss, and save lives. Zxerex hopes to play a very important role by helping employers with a safer workplace.

For further information, contact the IMPAIR-ID™ team at Zxerex, rb@zxerex.com or (480)518-9905.